Show initial efficacy data for the LIO-1 lucitanib and Opdivo combination trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- 4 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“show initial efficacy data for the LIO-1 lucitanib and Opdivo combination trial at a medical meeting this year”
What we found
Evidence strength A What the grades mean
The company presented interim efficacy data from the LIO-1 study's non-clear cell ovarian cancer expansion cohort at the ASCO 2021 annual meeting, which took place in June 2021.
-
A Clovis Oncology, Inc. 10-K filed 2022-02-24
“Interim data from the non-clear cell ovarian cancer expansion cohort were presented at ASCO 2021” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Show
- Deliverable
- LIO-1 lucitanib and Opdivo combination trial efficacy data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Clovis Oncology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C466301-021622 · Corrections policy